Kirkland’s Regeneron-Novartis Roles Spark Removal Bid (Correct)

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and patent dispute, saying the law firm wrongly switched sides despite a conflict.

Kirkland worked for Regeneron between 2020 and 2022 to develop a global intellectual property strategy to protect its eye-disease medication known as EYLEA, a lawyer for the pharmaceutical company said in a court filing on Tuesday.

Now, Kirkland represents Novartis against claims that the company colluded to prevent Regeneron from offering EYLEA in the US. “It should be unthinkable that Kirkland would litigate this case against Regeneron,” Kimo Peluso, ...